• LAST PRICE
    1.2500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.1800/ 1
  • Ask / Lots
    1.3200/ 3
  • Open / Previous Close
    --- / 1.2500
  • Day Range
    ---
  • 52 Week Range
    Low 0.4986
    High 1.7200
  • Volume
    26
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.26
TimeVolumeSLS
09:32 ET272931.215
09:34 ET701711.18
09:36 ET199601.19
09:38 ET1246661.0904
09:39 ET495531.12
09:41 ET269151.13
09:43 ET509131.15
09:45 ET281211.16
09:48 ET74061.15
09:50 ET262051.1593
09:52 ET100511.165
09:54 ET129091.1891
09:56 ET231881.189
09:57 ET13501.1798
09:59 ET93671.175
10:01 ET152191.18
10:03 ET297301.19
10:06 ET164271.2099
10:08 ET25921.205
10:10 ET355741.2399
10:12 ET1001.2207
10:14 ET39501.21
10:15 ET326951.21
10:17 ET5561.2109
10:19 ET1311.2104
10:21 ET68011.21
10:24 ET30001.2108
10:26 ET4701.2112
10:32 ET3001.21
10:35 ET2001.2189
10:37 ET1001.215
10:39 ET11001.2111
10:44 ET140501.23
10:46 ET52001.22
10:48 ET2001.2301
10:53 ET206621.245
10:55 ET71871.24
10:57 ET3031.24
11:00 ET37001.24
11:02 ET138001.24
11:04 ET7001.23
11:09 ET1001.235
11:13 ET57001.23
11:18 ET1001.235
11:20 ET12951.23
11:22 ET3001.23
11:24 ET1001.2301
11:26 ET1001.235
11:29 ET1411.2301
11:33 ET1001.235
11:36 ET34001.2398
11:38 ET48871.23
11:40 ET20881.23
11:42 ET239841.235
11:44 ET28001.23
11:45 ET17591.2397
11:47 ET23351.2301
11:49 ET28971.23
11:54 ET30441.24
11:56 ET4001.2311
11:58 ET24271.24
12:00 ET20001.24
12:02 ET14501.231
12:03 ET2501.2301
12:05 ET44111.2388
12:07 ET1501.2301
12:09 ET70051.22
12:12 ET5001.2201
12:14 ET1001.225
12:16 ET76501.22
12:21 ET1001.222
12:30 ET1001.225
12:34 ET3601.2216
12:36 ET15001.2265
12:38 ET1431.22
12:39 ET1001.22
12:41 ET1001.225
12:43 ET1001.2299
12:50 ET8001.2209
12:52 ET1001.225
12:56 ET2001.225
12:57 ET1001.22
12:59 ET1651.225
01:03 ET1001.225
01:06 ET39001.22
01:08 ET7501.2215
01:10 ET1001.22
01:15 ET5901.23
01:17 ET2961.2201
01:19 ET26051.22
01:26 ET1001.225
01:33 ET168651.215
01:35 ET45831.2
01:37 ET221541.21
01:39 ET10001.215
01:42 ET104521.229
01:44 ET3621.2253
01:46 ET2501.2212
01:48 ET23001.2201
01:50 ET1471.2213
01:53 ET4001.22
02:00 ET5001.2291
02:04 ET1001.225
02:08 ET1001.225
02:13 ET1001.225
02:15 ET1001.225
02:18 ET112191.23
02:20 ET1941.2201
02:22 ET3001.225
02:24 ET5001.23
02:27 ET24001.225
02:29 ET5001.2201
02:31 ET2501.225
02:33 ET1111.2213
02:36 ET2001.2212
02:42 ET4001.2225
02:45 ET1001.23
02:58 ET1111.2287
03:02 ET1001.23
03:07 ET101001.225
03:16 ET1001.23
03:20 ET26651.2299
03:23 ET1001.22
03:25 ET48311.22
03:27 ET11001.2293
03:36 ET54491.2299
03:38 ET64811.2306
03:39 ET26001.2306
03:41 ET39091.2312
03:45 ET1001.24
03:48 ET4001.235
03:50 ET50001.2302
03:52 ET78501.245
03:54 ET35051.245
03:57 ET208251.24
03:59 ET160591.25
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLS
Sellas Life Sciences Group Inc
80.4M
-1.3x
---
United StatesCNTB
Connect Biopharma Holdings Ltd
79.6M
-3.7x
---
United StatesGNLX
Genelux Corp
81.8M
-2.4x
---
United StatesBOLD
Boundless Bio Inc
77.2M
-1.3x
---
United StatesPMVP
PMV Pharmaceuticals Inc
76.8M
-1.5x
---
United StatesALRN
Aileron Therapeutics Inc
76.7M
-1.1x
---
As of 2024-10-01

Company Information

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Contact Information

Headquarters
7 TIMES SQUARE, SUITE 2503NEW YORK, NY, United States 10036
Phone
646-200-5278
Fax
925-498-7799

Executives

Independent Chairman of the Board
Jane Wasman
President, Chief Executive Officer, Director
Angelos Stergiou
Chief Financial Officer
John Burns
Senior Vice President - Clinical Development
Dragan Cicic
Vice President - Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality
Andrew Elnatan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$80.4M
Revenue (TTM)
$0.00
Shares Outstanding
64.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.39
EPS
$-0.93
Book Value
$-0.25
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.